Proceedings · Session S-467 · filed November 19, 2026

Corporate & Industrial R&DSession paper

Nine California biotechs cut at least half their workforces in 2026

California biopharma layoffs and projections reach at least 1,176 in 2026. Nine companies are cutting at least half their staffs, with two closures and pipeline withdrawals changing R&D risk.

By Rebecca Stone5 min read1,010 words

Summary

  • 24 biopharma companies have reported or projected 1,176 California job cuts in 2026.
  • Nine companies are eliminating at least half their workforces; two closed and seven are cutting at least 60%.
  • Gilead is cutting 193 California jobs, including 108 Arcellx positions dismissed in June.
  • Caribou plans 87 dismissals for Dec. 7, while Artiva plans 131 for Dec. 31.
  • Tempest cut three of four full-time workers; Calidi's reduction may affect about 19 people.
9 biotechs will cut at least half their California workforces
Figure9 biotechs will cut at least half their California workforces — AI-generated

California biopharma employers have reported or projected 1,176 job cuts in 2026, according to BioSpace tallies, and nine companies are eliminating at least half their workforces. The figures cover 24 biopharmas; 38% are removing at least half their staffs, while two have shut down.

Among the nine, f5 Therapeutics and Tempero Bio eliminated their entire workforces through closure. The other seven are cutting at least 60% of employees. For R&D managers, this is not a uniform reduction in capacity: whole companies and development programs are disappearing or being narrowed.

The broader tally spans small biotechs and large pharmas. Gilead has the largest absolute reduction. Foster City-based Gilead is cutting 193 California employees, including 108 Arcellx employees dismissed in June at the wholly owned subsidiary's Redwood City headquarters. AbbVie, BioMarin Pharmaceutical, Genentech and Takeda also appear in the tally, but no separate figures were reported for those four.

Five of the nine major reductions were announced or disclosed in the fourth quarter, although layoffs began in the first quarter. The clustering brings fixed-cost exits into the same planning window as year-end financing and vendor commitments.

Why did the first two companies close?

In March, f5 Therapeutics CEO Gary Choy wrote on LinkedIn that “the past few years had been brutal for early stage biotechs” as the company closed. Its LinkedIn page showed fewer than 10 employees, so the shutdown likely affected a small group.

Before closing, f5 had identified 11 potential targets using molecular glues developed through its proprietary NExMod platform. The platform used phenotypic screening, or testing biological readouts to find novel targets for previously undruggable conditions.

Tempero followed in April after Endpoints News reported that it would shutter following a serious adverse event in a Phase 2 alcohol use disorder trial of lead candidate TMP-301. The program addressed the neurobiological basis of addiction.

CEO Paul Johnson did not disclose what happened in the study. Tempero's LinkedIn page showed between two and 10 employees in April, so its closure erased a small company rather than trimming a large operating organization.

Which operating teams lost staff?

In August, San Diego-based aTyr Pharma said it would lay off about 60% of staff, likely affecting around 30 people in California. It redirected resources toward efzofitimod for interstitial lung disease (ILD), which causes lung inflammation and scarring.

CFO Jill Broadfoot and General Counsel Nancy Denyes stepped down Sept. 30 and moved into consultant roles, extending the change into finance and legal oversight.

About a month later, an Arsenal Biosciences spokesperson told BioSpace that the biotech “was laying off 99 employees, representing most of the company.” The cuts covered its South San Francisco headquarters and a Hayward site and likely equaled 78% of the workforce, based on the latest known headcount.

Arsenal accompanied the cuts with a shift toward in vivo CAR T therapies, which generate CAR T cells inside the body, while exploring strategic opportunities for its assets and technologies.

Caribou Biosciences opened the fourth-quarter sequence in October. The Berkeley-based company said a financing freeze in the CAR T space had led it to discontinue further development of its clinical-stage pipeline (programs in human testing), implement a “substantial” workforce reduction and explore strategic alternatives.

A Worker Adjustment and Retraining Notification (WARN) Act notice set 87 dismissals at Caribou's lone location for Dec. 7, potentially 90% of its workforce. Options include a merger, acquisition, business combination or another strategic transaction involving the company and its assets.

Late in October, San Diego-based Artiva Biotherapeutics halted development of its lead candidate after two patient deaths and questions about the durability of the clinical response. It also said it would cut about 94% of staff and explore strategic alternatives.

A WARN notice put 131 Artiva dismissals at its sole location on Dec. 31. Options include a merger, business combination, sale or licensing of assets, or dissolution and liquidation.

The next day, LENZ Therapeutics announced a reorganization to streamline the organization and prioritize resources and capital for initiatives expected to have the highest sales impact. An SEC filing put the reduction at about 75%, likely around 120 people at its Solana Beach headquarters.

LENZ expected to complete the reorganization by year-end. President and CEO Eef Schimmelpennink's last day was Dec. 1, placing a senior leadership departure alongside the workforce cut.

What do the latest filings show?

Two further rounds appeared in the latest quarterly earnings reports. Brisbane-based Tempest Therapeutics had cut 80% of staff in April 2025, then cut three of four full-time workers, or 75%, between June and September.

Tempest is developing in vivo CAR T therapies for cancer and autoimmune disease and remains supported by external consultants and service providers. The report does not quantify those external commitments.

San Diego-based Calidi Biotherapeutics disclosed plans to cut about 67% of staff to reduce costs, extend its cash runway (the period it can operate without new financing) and preserve capital while seeking additional financing.

Based on a headcount including German subsidiary StemVac GmbH, the reduction may affect about 19 people, but the California share is unspecified. Calidi expects to complete most cuts during the current quarter.

Calidi is also exploring a merger, acquisition, business combination or another strategic transaction involving the company and its assets.

What should R&D managers watch?

BioSpace excludes contract development and manufacturing organizations, contract research organizations, tools and services businesses, and medical device firms. It counts only known reductions, using confirmations from company officials, press releases, WARN notices, SEC filings and media reports to identify or estimate affected employees.

Not all companies disclose downsizing; some give only percentages, and others report totals retrospectively. The 1,176 figure therefore combines confirmed and estimated losses, while California headcount remains uncertain for aTyr, Arsenal and Calidi.

For R&D managers, the immediate watchpoints are the Dec. 7 and Dec. 31 separations, Calidi's financing effort and the strategic reviews at Arsenal, Caribou, Artiva and Calidi, which will show whether affected assets move through transactions or end in liquidation.

via biospace.com (Source)

Filed under

  • biotech-layoffs
  • biopharma-workforce-reduction
  • r-d-pipeline-strategy
  • biotech-financing
  • car-t
Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.

278 articles

References

  1. October Biopharma Layoffs Rise Year Over Year as Six Firms Cut Over Half Their Staff
  2. Biopharma Layoff Tracker 2026: Novo, GSK and Pfizer Drive Deep Cuts
  3. Agios cuts 100-plus R&D roles as FDA decision slips
  4. Cellectis to Cut up to 70% of Staff in Pivot to In Vivo Gene Editing
  5. U.S. bioscience jobs rose 7%; business count topped 156,000

« Previous article